Compare Addus HomeCare Corporation (ADUS) vs Fresenius Medical Care AG & Co. KGaA (FMS) Stock

Fresenius Medical Care AG & Co. KGaA (FMS) offers the better valuation at 11.8x trailing P/E (9.9x forward), making it the more compelling value choice. Analysts rate Addus HomeCare Corporation (ADUS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Fresenius Medical Care AG & Co. KGaA (FMS) is the cheapest at 11.8x versus Addus HomeCare Corporation at 19.9x. On forward P/E, Fresenius Medical Care AG & Co. KGaA is actually cheaper at 9.9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Addus HomeCare Corporation wins at 0.74x versus Fresenius Medical Care AG & Co. KGaA's 1.94x — a PEG below 1.0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Addus HomeCare Corporation (ADUS) delivered a total return of +1.0%, compared to -22.8% for Fresenius Medical Care AG & Co. KGaA (FMS). A $10,000 investment in ADUS five years ago would be worth approximately $10K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ADUS returned +356.1% versus FMS's -28.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Fresenius Medical Care AG & Co. KGaA (FMS) is the lower-risk stock at 0.40β versus Addus HomeCare Corporation's 0.41β — meaning ADUS is approximately 2% more volatile than FMS relative to the S&P 500. On balance sheet safety, Addus HomeCare Corporation (ADUS) carries a lower debt/equity ratio of 19% versus 76% for Fresenius Medical Care AG & Co. KGaA — giving it more financial flexibility in a downturn.

Addus HomeCare Corporation (ADUS) is the more profitable company, earning 6.7% net margin versus 5.0% for Fresenius Medical Care AG & Co. KGaA — meaning it keeps 6.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADUS leads at 9.7% versus 9.3% for FMS. At the gross margin level — before operating expenses — ADUS leads at 32.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Addus HomeCare Corporation (ADUS) is the more undervalued stock at a PEG of 0.74x versus Fresenius Medical Care AG & Co. KGaA's 1.94x. A PEG below 1.0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Fresenius Medical Care AG & Co. KGaA (FMS) trades at 9.9x forward P/E versus 15.0x for Addus HomeCare Corporation — 5.1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADUS: 28.2% to $132.75.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Addus HomeCare Corporation (ADUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.41), +356.1% 10Y return). Both have compounded well over 10 years (ADUS: +356.1%, FMS: -28.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: ADUS is a small-cap quality compounder stock; FMS is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.